Pfizer: skin disease drug shows positive results
(CercleFinance.com) - Pfizer said abrocitinib, its investigational drug for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin disease, showed positive results in a late-stage trial.
A Phase 3 pivotal study evaluating the efficacy and safety of the drug in patients aged 12 and over showed that by week 12 the percentage of patients achieving efficacy endpoints was statistically significantly higher than placebo.
In addition, the results demonstrated response to treatment for a statistically significant number of patients during the first two to four weeks following first dose, the group said.
Separately, Pfizer said that the US Food and Drug Administration (FDA) has approved Bavencio, an anticancer drug that the group is jointly developing with Germany's Merck, in combination with axitinib, for the first-line treatment of patients with advanced renal cell carcinoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
A Phase 3 pivotal study evaluating the efficacy and safety of the drug in patients aged 12 and over showed that by week 12 the percentage of patients achieving efficacy endpoints was statistically significantly higher than placebo.
In addition, the results demonstrated response to treatment for a statistically significant number of patients during the first two to four weeks following first dose, the group said.
Separately, Pfizer said that the US Food and Drug Administration (FDA) has approved Bavencio, an anticancer drug that the group is jointly developing with Germany's Merck, in combination with axitinib, for the first-line treatment of patients with advanced renal cell carcinoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.